BOARD OF PHARMACY
Professional and Vocational Licensing Division
Department of Commerce and Consumer Affairs
State of Hawaii
WORKING GROUP MEETING AGENDA
Date: Thursday, August 16, 2018
Time: Immediately following the Board meeting (approx. time 9:30 a.m.)
Place: Queen Liliuokalani Conference Room, First Floor
King Kalakaua Building
335 Merchant Street
Honolulu, Hawaii 96813
1. Call to Order, Public Notice – HRS §92-3 Open Meetings and HAR §16-89-70 Oral Testimony
2. Report from July 19, 2018 meeting.
3. Update on 2018 Legislation
a. SB 2247, SD1, HD2, CD1 Relating to Opioid Antagonists – Authorizes pharmacists to prescribe, dispense, and provide related education on opioid antagonists to individuals at risk of opioid overdose and to family members and caregivers of individuals at risk of opioid overdose without the need for a written, approved collaborative agreement; subject to certain conditions. (CD1) – Approved by the Governor on 7/9/2019, Act 154, SLH 2018
• Can pharmacist “prescribe” but not dispense opioid antagonist?
• Draft of Bill
b. HB 2739, HD1 – Relating to Health - Establishes a regulated process under which an adult resident of the State with a medically confirmed terminal disease and less than six months to live may choose to obtain a prescription f or medication to end the patient's life. Imposes criminal sanctions for tampering with a patient's request for a prescription or coercing a patient to request a prescription. (HB2739 HD1) – Act 2, SLH 2018
• Immunities/ basis for prohibiting health care provider from participation…
4. Discussion of Issues Raised at July Meeting – Refer to Attached Report:
1. Group to Prioritize Issues
2. How To Address, i.e. Legislation, Amend Admin Rules
3. Divide Issues and Group into Committees to Research and Report Back to the Group
5. Next Meeting: September 20, 2018
Immediately following the Board of Pharmacy meeting
Queen Liliuokalani Conference Room
King Kalakaua Building
335 Merchant Street, First Floor
Honolulu, Hawaii 96813
Individuals who require special needs accommodations are invited to call Lee Ann Teshima, Executive Officer, at (808) 586-2695 at least 4 working days in advance of the meeting.
Report on July 19, 2018 Pharmacy Working Group Meeting
Start: 10:30 a.m.
Kellie Noguchi, Kaiser
Stacy Pi, Kaiser
Wesley Sumida, Daniel K. Inouye, College of Pharmacy (“DKICOP”)
Pono Chong, HMSA
Jacce Mikulanec, HMSA
Stacy Lu, DKICOP
Preston Ho, DKICOP
Sabine Sananura, DKICOP
Kevin Lei, DKICOP
Patrick Uyemoto, Times/HPhA
Glenn Wasserman, DOH
Fred Cruz, CVS Caremark
Reece Uyeno, Pharmacare
Mary Jo Keefe, Pharmerica
Carolyn Ma, DKICOP
Laruen Glover Alejado, DKICOP
Athena Borhauer, DKICOP
Tiffany Yajima, Ashford & Wriston/Walgreens
Alanna Isobe, Safeway
Lee Ann Teshima, Executive Officer (“EO”), Board of Pharmacy
Act 154, SLH 2018 Relating to Opioids
Recommendation to submit legislation to “fix” the language pertaining to the name on the prescription to include “or requested” on page 3, line 17 of the Act.
HPhA As part of Workgroup 5 of the Statewide Opioid Task Force, Mr. Uyemoto reported on the new Hawaii Opioid web site: www.hawaiiopioid.org, that went live on or about 7/18/2018
DOH Asked the EO for the Board of Pharmacy (“Board”) if a pharmacist had to “prescribe and dispense” or could the pharmacist “prescribe” but not dispense the opioid antagonist.
The EO speculated that the law was very specific but that she would place this question on the Board’s August agenda for discussion.
HPhA Asked if the Board would be maintaining a list of pharmacists/pharmacies who would be prescribing and dispensing opioid antagonists?
The EO stated that the Board could maintain a list of participating pharmacists/pharmacies by way of the pharmacist submitting proof of completion of the opioid training.
Mr. Uyemoto also stated that we have no way of knowing that the pharmacy would be stocking the opioid antagonist.
DKICOP Dr. Ma stated that the take back of drugs for disposal is a topic that should be discussed and that other states have programs that are “funded” by manufacturers, wholesale distributors, etc. She also referred to HAR §16-95-87 regarding the return or exchange of drugs prohibited and that perhaps this section should be reviewed and possibly amended.
Students from the DKICOP shared information on their research of other states with approved drug disposal programs.
DOH Mentioned that reimbursement is an issue if any further expansion of the pharmacy scope of practice is going to be discussed.
Dr. Ma recommended that focus on reimbursement should be on the “current” scope of practice.
HMSA Mentioned a payment transformation and reimbursement for women’s contraception.
DKICOP Dr. Ma stated that there needs to be more data collection on how the current scope of practice is effective in providing more access to healthcare by pharmacists.
Pharmacare Mr. Uyeno suggested including chronic care management in the pharmacy scope of practice and to include collaborative practice.
DOH Recommended the medical care home model.
End: 11:30 a.m.